Supplier News Breaks Archives
Endo Health COO, CFO leaving company
May 29th, 2013
MALVERN, Pa. – Endo Health Solutions Inc. has announced the departure of Julie McHugh, chief operating officer, and Alan Levin, executive vice president and chief financial officer.
The pharmaceutical and health care products company said Wednesday that McHugh's departure is effective immediately. No other details were disclosed.
"The board and I want to thank Julie for her dedicated service and significant contributions to building Endo into one of the leading public diversified health care companies," president and chief executive officer Rajiv De Silva said in a statement.
Plans call for Levin to continue in his current role until the fall while a search is conducted for his successor.
"Endo is a great company, and I am confident that it will do well in this next phase in its evolution," Levin stated. "I am proud to have played a role in its growth and diversification during my tenure as chief financial officer. After 20 years in corporate executive positions — the last four of which have been at Endo — I look forward to a fulfilling new chapter in my life and plan to be active in corporate board service and philanthropy, while traveling and spending more time with my family."
Endo said its board has formed a search committee and engaged a leading search firm to assist in an external search for a new CFO.
De Silva commented, "The board and I want to thank Alan for his dedicated service and significant contributions to building Endo into one of the leading public diversified healthcare companies. I also want to recognize Alan's contributions to the ongoing assessment of the company's strategy and operations, which I launched upon my arrival at Endo. We expect a smooth transition and are confident in the plans we are putting in place to position Endo for the future and drive shareholder value."
Earlier this year, Endo named De Silva president and CEO to succeed the retiring David Holveck. De Silva, who took the helm as CEO in mid-March, previously was president of Valeant Pharmaceuticals.